Equities Analysts Set Expectations for LRMR FY2025 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Stock analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for Larimar Therapeutics in a report issued on Tuesday, March 25th. HC Wainwright analyst E. White now forecasts that the company will post earnings of ($1.91) per share for the year, down from their prior estimate of ($1.77). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ FY2026 earnings at ($2.10) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.16).

LRMR has been the topic of several other research reports. Robert W. Baird dropped their price target on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday. Truist Financial assumed coverage on shares of Larimar Therapeutics in a research note on Wednesday, January 29th. They set a “buy” rating and a $18.00 price objective on the stock. Finally, Guggenheim restated a “buy” rating and issued a $26.00 target price on shares of Larimar Therapeutics in a research report on Tuesday. Eleven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Larimar Therapeutics has a consensus rating of “Buy” and a consensus price target of $20.22.

Larimar Therapeutics Stock Down 2.6 %

Shares of NASDAQ LRMR opened at $2.25 on Thursday. The stock has a market cap of $143.57 million, a P/E ratio of -1.96 and a beta of 0.99. The firm’s 50-day simple moving average is $3.11 and its 200 day simple moving average is $5.18. Larimar Therapeutics has a fifty-two week low of $2.19 and a fifty-two week high of $11.20.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Fi3 FINANCIAL ADVISORS LLC lifted its position in shares of Larimar Therapeutics by 16.7% during the 4th quarter. Fi3 FINANCIAL ADVISORS LLC now owns 23,798 shares of the company’s stock valued at $92,000 after acquiring an additional 3,411 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Larimar Therapeutics by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 21,771 shares of the company’s stock worth $143,000 after purchasing an additional 3,425 shares during the period. Franklin Resources Inc. raised its position in shares of Larimar Therapeutics by 21.9% during the third quarter. Franklin Resources Inc. now owns 19,723 shares of the company’s stock worth $143,000 after purchasing an additional 3,549 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of Larimar Therapeutics by 12.3% during the fourth quarter. Envestnet Asset Management Inc. now owns 35,525 shares of the company’s stock valued at $137,000 after purchasing an additional 3,877 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Larimar Therapeutics by 8.1% in the 4th quarter. Bank of America Corp DE now owns 53,190 shares of the company’s stock valued at $206,000 after purchasing an additional 3,980 shares during the period. Institutional investors and hedge funds own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.